NCT01907906已完成1 期
Inactivation of Whole Blood With Mirasol : Performance in Red Blood Cells in Healthy Volunteers
Terumo BCTbio4 个研究点 分布在 1 个国家目标入组 29 人开始时间: 2013年6月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 29
- 试验地点
- 4
- 主要终点
- Red Blood Cell (RBC) 24-Hour Recovery
研究概览
简要总结
The purpose of this study is to evaluate radiolabeled recovery and survival of autologous red blood cells (RBC), derived from Mirasol-treated fresh whole blood (WB), stored as leukoreduced packed RBC (LR-pRBC), and re-infused in healthy adult subjects
详细描述
This is a feasibility level study conducted to assess the recovery and survival of autologous, radiolabeled leukoreduced packed red blood cells (LR-pRBC) derived from fresh whole blood (WB) units that have been treated with the Mirasol System for Whole Blood (Mirasol System) and stored for 21 days at 1-6°C.1
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Eligible whole blood donor
- •Age ≥ 18 years, of either sex
- •Able to commit to the study follow-up schedule
- •Subjects must have adequate bilateral antecubital venous access for WB collection and follow-up blood draws
- •Negative screening test panel for infectious diseases
- •Subjects of child-bearing potential (female or male) must agree to use effective contraceptive during the course of the study per site guidelines
- •Subjects must agree to report adverse events (AEs) during the required reporting period
- •Negative direct antiglobulin test (DAT) with subject's RBC
- •Negative indirect antiglobulin test (IAT) with subject's serum
- •Inclusion for radiolabeled reinfusion of LR-pRBC on Day 21 (evaluated the day of, prior to, reinfusion):
- •Maintenance of healthy status
- •Negative direct antiglobulin test (DAT) with subject's RBC (fresh)
- •Negative indirect antiglobulin test (IAT) with subject's serum (fresh) versus autologous stored LR-pRBC
- •Negative serum or urine pregnancy test in females
排除标准
- •Any serious medical illness and/or therapy, including: abnormal bleeding episodes, clotting or bleeding disorder, evidence of anemia, myocardial infarction, uncontrolled hypertension, heart disease, surgery with bleeding complications, epilepsy or any major surgery (with general or spinal anesthesia) within the last 6 months
- •Pregnant or nursing females; For women of childbearing potential, negative serum or urine pregnancy tests at the time of WB donation and before the reinfusion are required
- •Unable to give informed consent
- •Participation currently, or within the last 12 months, in another investigational trial that would potentially interfere with the analysis of this investigation (e.g., pharmaceutical)
- •Have received an accumulated radiation dose that would exclude them from the study according to the local radiation safety limits established by each institution
- •Inability to comply with the protocol in the opinion of the investigator
结局指标
主要结局
Red Blood Cell (RBC) 24-Hour Recovery
时间窗: 24 hours
To evaluate, as per FDA criteria, the 24-hour post transfusion RBC recovery in healthy adult subjects of leuko-reduced packed red blood cells (LR-pRBC) that have been derived from Mirasol-treated fresh WB units and stored at 1 to 6°C for 21 days. 24-hour RBC Recovery is a measure of the % of RBCs that are still functioning 24 hours after they have been reinfused back into the donor following storage over 21 days.
次要结局
- Spearman's Correlation Coefficients: 24-Hour RBC Recovery (%) With Adenosine Triphosphate (ATP) (µmol/g Hgb)(24 hours)
- Spearman's Correlation Coefficients: 24-Hour RBC Recovery (%) pCO2 (mmHg at 37° C)(24 hours)
- Spearman's Correlation Coefficients: Linear T50 (Days) With Hemolysis (%)(28 days)
- In Vitro Results From Leuko-Reduced Packed Red Blood Cells (LR-pRBCs) - Hematocrit (%)(Day 21)
- In Vitro Results From Leuko-Reduced Packed Red Blood Cells (LR-pRBCs) - Hemolysis (%)(Day 21)
- Red Blood Cell (RBC) Survival by Product(28 days)
- Neoantigenicity - Day 21 Direct Antigen Test (DAT)(Day 21)
- Neoantigenicity - Day 42 Direct Antigen Test (DAT)(Day 42 of Treatment Periods 1 and 2)
- In Vitro Results From Leuko-Reduced Packed Red Blood Cells (LR-pRBCs) - White Blood Cell (WBC) Count(Day 21)
- In Vitro Results From Leuko-Reduced Packed Red Blood Cells (LR-pRBCs) - Total Hemoglobin(Day 21)
- In Vitro Results From Leuko-Reduced Packed Red Blood Cells (LR-pRBCs) - pH (at 37° C)(Day 21)
- In Vitro Results From Leuko-Reduced Packed Red Blood Cells (LR-pRBCs) - Potassium(Day 21)
- In Vitro Results From Leuko-Reduced Packed Red Blood Cells (LR-pRBCs) - Glucose(Day 21)
- Area Under the Curve (AUC) of Red Blood Cell (RBC) Survival(28 days)
- Spearman's Correlation Coefficients: Linear T50 (Days) With pCO2 (mmHg at 37° C)(28 days)
- Neoantigenicity - Day 42 Indirect Antigen Test (IAT)(Day 42 of Treatment Periods 1 and 2)
- In Vitro Results From Leuko-Reduced Packed Red Blood Cells (LR-pRBCs) - ATP(Day 21)
- In Vitro Results From Leuko-Reduced Packed Red Blood Cells (LR-pRBCs) - 2,3-diphosphoglycerate (DPG)(Day 21)
- Spearman's Correlation Coefficients: 24-Hour Red Blood Cell (RBC) Recovery (%) With Hemolysis (%)(24 hours)
- Spearman's Correlation Coefficients: Linear T50 (Days) With Adenosine Triphosphate (ATP) (µmol/g Hgb)(28 days)
- In Vitro Results From Leuko-Reduced Packed Red Blood Cells (LR-pRBCs) - pCO2 (mmHg at 37° C)(Day 21)
- In Vitro Results From Leuko-Reduced Packed Red Blood Cells (LR-pRBCs) - Lactate(Day 21)
- Neoantigenicity - Day 21 Indirect Antigen Test (IAT)(Day 21 of Treatment Periods 1 and 2)
- In Vitro Results From Leuko-Reduced Packed Red Blood Cells (LR-pRBCs) - Supernatant Hgb(Day 21)
研究者
研究点 (4)
Loading locations...
相似试验
终止
1 期
Feasibility Study of Mirasol-Treated Whole Blood Red Cell Recovery and SurvivalHealthyNCT00742001Terumo BCTbio12
已完成
不适用
Clinical and Biological Efficacy of Mirasol-treated Fresh Whole Blood for the Prevention of Transfusion-transmitted MalariaMalariaNCT02118428Terumo BCTbio227
已完成
不适用
Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL AmyloidosisAmyloidosisNCT02716103Boston Medical Center45
已完成
1 期
Safety Study of ECO Conversion System For Red Blood Cells.AnemiaNCT00261274Velico Medical60
已完成
不适用
Measuring the survival of transfused red blood cells in patients with Sickle cell disease and b-Thalassemia: A Biotin Label approachSickle cell diseaseNL-OMON50011Academisch Medisch Centrum15